| Autor: |
Waters LJ; Department of Genitourinary/HIV Medicine, Chelsea and Westminster Hospital Foundation Trust, London, United Kingdom., Scourfield AT, Marcano M, Gazzard BG, Bower M, Nelson M, Stebbing J |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2011 Mar 01; Vol. 52 (5), pp. 671-3. |
| DOI: |
10.1093/cid/ciq198 |
| Abstrakt: |
CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze tropism evolution during fully suppressive antiretroviral therapy (ART). Two of 37 patients showed evidence of switching. Tropism switching after suppressive ART was uncommon in this cohort. Pretreatment human immunodeficiency virus (HIV) RNA tropism testing may help guide the switch to CCR5 antagonists in patients with undetectable HIV RNA. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
